Phase I Trial of Docetaxel With Perifosine - Full Text View

Sponsored by:	AOI Pharma, Inc.
Information provided by:	AOI Pharma, Inc.
ClinicalTrials.gov Identifier:	NCT00399087

Purpose

This is a study of the drug perifosine given in combination with docetaxel. Perifosine is an oral anti-cancer agent that has been used in more than 140 people. Docetaxel is a standard chemotherapy agent used in many types of cancer. This study is designed to determine the highest dose of perifosine that can be administered to people every day while they are receiving docetaxel with or without a steroid called prednisone, without severe or prolonged nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up to 150 mg/day.

Condition	Intervention	Phase
Neoplasms	Drug: Perifosine Drug: Docetaxel Drug: Prednisone	Phase I

MedlinePlus related topics: Cancer Nausea and Vomiting

Drug Information available for: Prednisone Docetaxel Perifosine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study
Official Title:	A Phase 1 Trial of the Combination of Perifosine and Docetaxel With or Without Prednisone

Further study details as provided by AOI Pharma, Inc.:

Primary Outcome Measures:

GI Toxicities

Secondary Outcome Measures:

Other toxicities
Disease progression

Estimated Enrollment:	30
Study Start Date:	November 2004
Estimated Study Completion Date:	June 2009
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Detailed Description:

This is a phase 1, open-label trial of perifosine and docetaxel with or without prednisone in patients with malignancies for whom single agent docetaxel is a reasonable treatment option. All patients will receive docetaxel at a dose of 75 mg/m2 on day 8 of a 21-day cycle either without (Arm A) or with prednisone 5 mg bid on days 1 - 21 (Arms B and C). (Patients on all arms will receive premedication with dexamethasone around the time of docetaxel administration either as described in the product insert for arm A or as used in prior prostate cancer phase III studies for arm B and C. The 1st cohort of patients on Arm A and Arm B will receive perifosine orally at a dose of 50 mg per day for the first 14 days of the 21-day cycle. On each arm, the perifosine dose will be escalated in subsequent groups to 50 mg bid and then 50 mg tid as tolerated. Alternating cohorts of 3 patients will be entered first to Arm A and then to Arm B. At the completion of arms A and B, 3 cohorts of patients will be entered who will receive perifosine weekly at doses of 900, 1200 and 1500 mg. The total dose will be divided into 300 mg doses which will be delivered at least 4 hours apart. The perifosine dose escalation for each arm will be performed separately according to the following algorithm. For each arm, a maximum tolerated dose (MTD) will be defined as a dose that can be given without grade 3/4 non-hematologic toxicity in more than 1/3 patients. If 2/3 patients in any cohort encounter a grade 3/4 non-hematologic toxicity, an additional 3 patients will be added. If the dose is intolerable for >3/6 patients then the previous dose level will be declared the MTD for that arm.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients must have histologically or cytologically confirmed diagnosis of cancer for which treatment with single agent docetaxel would be an appropriate treatment option.
At least 18 years of age.
Patients may be currently receiving docetaxel using the schedule in the protocol, as long as the treating investigator has reasonable expectation that the patient will continue to receive docetaxel for 2 or more additional cycles. The current regimen does not count towards the 2 regimens as long as the patient is not progressing on therapy..
Patients must have a life expectancy of more than 3 months.
Patients must have a performance status of 0 to 2 according to the ECOG criteria.
Patients must have normal organ and marrow function as defined in the protocol: leukocytes >=4,000/microL, absolute neutrophil count >=1,500/microL, platelets >=100,000/microL, HCT > 28%, total bilirubin < 1.5 x upper limit of normal, AST (SGOT)/ALT (SGPT) <=2.5 X institutional upper limit of normal, creatinine <= 2.5 mg/dl
Patients must have recovered from acute toxicity related to prior therapy, excluding alopecia, including surgery or radiotherapy.
Patients must be able to ingest oral medications.
Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for four weeks after the completion of treatment.
Patients must have ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Patients may not be receiving any other investigational agents or devices.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements.
HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine.
Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class II-IV congestive heart failure.
Patients with a history of hypersensitivity reaction to products containing Polysorbate 80 (Tween 80).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00399087

Locations

United States, Tennessee
AOI Pharmaceuticals Investigative Site
Johnson City, Tennessee, United States, 37604

Sponsors and Collaborators

AOI Pharma, Inc.

Investigators

Study Director:

Robert Birch, Ph.D.

AOI Pharma, Inc.

More Information

No publications provided

Responsible Party:	AOI Pharmacuticals ( AOI Pharmacuticals )
Study ID Numbers:	Perifosine 105
Study First Received:	November 10, 2006
Last Updated:	February 13, 2009
ClinicalTrials.gov Identifier:	NCT00399087 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Anti-Inflammatory Agents
Docetaxel
Prednisone
Antineoplastic Agents, Hormonal

Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Glucocorticoids

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Docetaxel
Prednisone
Neoplasms
Antineoplastic Agents, Hormonal
Antineoplastic Agents

Therapeutic Uses
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Glucocorticoids
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009